August 1, 2017
Celgene, Agios get FDA’s approval for AML treatment IDHIFA
Celgene Corporation and Agios Pharmaceuticals, Inc. today announced that IDHIFA was granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test.